Columbus Circle Investors raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 6.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 490,729 shares of the medical research company’s stock after buying an additional 29,531 shares during the period. Columbus Circle Investors owned about 0.23% of Edwards Lifesciences Corporation worth $58,024,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of EW. Jennison Associates LLC raised its stake in Edwards Lifesciences Corporation by 0.5% in the second quarter. Jennison Associates LLC now owns 973,058 shares of the medical research company’s stock worth $115,054,000 after buying an additional 4,832 shares in the last quarter. Financial Advisors Network Inc. purchased a new stake in Edwards Lifesciences Corporation during the second quarter worth approximately $469,000. Turner Investments LLC purchased a new stake in Edwards Lifesciences Corporation during the second quarter worth approximately $1,301,000. Blair William & Co. IL raised its stake in Edwards Lifesciences Corporation by 12.6% in the second quarter. Blair William & Co. IL now owns 510,702 shares of the medical research company’s stock worth $60,385,000 after buying an additional 57,347 shares in the last quarter. Finally, Pegasus Partners Ltd. purchased a new stake in Edwards Lifesciences Corporation during the second quarter worth approximately $236,000. 84.67% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation (EW) opened at 113.11 on Monday. The firm has a market cap of $23.88 billion, a P/E ratio of 34.31 and a beta of 0.63. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The firm’s 50-day moving average is $116.42 and its 200 day moving average is $106.02.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. During the same quarter last year, the firm posted $0.76 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/21/columbus-circle-investors-raises-stake-in-edwards-lifesciences-corporation-ew.html.

A number of equities research analysts have recently commented on EW shares. Stifel Nicolaus upped their price objective on shares of Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the company a “buy” rating in a research note on Wednesday, April 26th. Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday, April 26th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Vetr lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating and set a $110.88 price objective on the stock. in a research note on Wednesday, April 26th. Finally, Goldman Sachs Group, Inc. (The) started coverage on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $120.18.

In other news, VP Donald E. Bobo, Jr. sold 5,600 shares of the stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $117.15, for a total transaction of $656,040.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total value of $3,816,071.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,281 shares of company stock worth $17,331,446. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.